Literature DB >> 20554818

Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection.

J C Lindow1, F Poly, D R Tribble, P Guerry, M P Carmolli, S Baqar, C K Porter, K K Pierce, M J Darsley, K S Sadigh, E A Dill, B D Kirkpatrick.   

Abstract

We report the first instance of macrolide resistance developing in vivo following appropriate antibiotic use in a healthy volunteer as a part of a controlled human infection with Campylobacter jejuni. In vivo development of macrolide resistance may be an important contributor to antibiotic resistance in C. jejuni.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20554818      PMCID： PMC2916616          DOI： 10.1128/JCM.00768-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  23 in total

1.  Practice guidelines for the management of infectious diarrhea.

Authors:  R L Guerrant; T Van Gilder; T S Steiner; N M Thielman; L Slutsker; R V Tauxe; T Hennessy; P M Griffin; H DuPont; R B Sack; P Tarr; M Neill; I Nachamkin; L B Reller; M T Osterholm; M L Bennish; L K Pickering
Journal:  Clin Infect Dis       Date:  2001-01-30       Impact factor: 9.079

Review 2.  Typhoid fever.

Authors:  Christopher M Parry; Tran Tinh Hien; Gordon Dougan; Nicholas J White; Jeremy J Farrar
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

3.  Detection of mutations associated with macrolide resistance in thermophilic Campylobacter spp. by real-time PCR.

Authors:  Sylvie Vacher; Armelle Menard; Elisabeth Bernard; Adriana Santos; Francis Megraud
Journal:  Microb Drug Resist       Date:  2005       Impact factor: 3.431

4.  Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure.

Authors:  Naidan Luo; Sonia Pereira; Orhan Sahin; Jun Lin; Shouxiong Huang; Linda Michel; Qijing Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-05       Impact factor: 11.205

5.  Macrolide resistance in Campylobacter jejuni and Campylobacter coli: molecular mechanism and stability of the resistance phenotype.

Authors:  Amera Gibreel; Veronica N Kos; Monika Keelan; Cathy A Trieber; Simon Levesque; Sophie Michaud; Diane E Taylor
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  PCR-restriction fragment length polymorphism analysis for detection of point mutations associated with macrolide resistance in Campylobacter spp.

Authors:  Sylvie Vacher; Armelle Ménard; Elisabeth Bernard; Francis Mégraud
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

7.  Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Authors:  David R Tribble; Shahida Baqar; Daniel A Scott; Michael L Oplinger; Fernando Trespalacios; David Rollins; Richard I Walker; John D Clements; Steven Walz; Paul Gibbs; Edward F Burg; Anthony P Moran; Lisa Applebee; A Louis Bourgeois
Journal:  Infect Immun       Date:  2010-01-19       Impact factor: 3.441

Review 8.  Public health consequences of use of antimicrobial agents in food animals in the United States.

Authors:  Alicia D Anderson; Jennifer M Nelson; Shannon Rossiter; Frederick J Angulo
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

9.  Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent.

Authors:  R A Kuschner; A F Trofa; R J Thomas; C W Hoge; C Pitarangsi; S Amato; R P Olafson; P Echeverria; J C Sadoff; D N Taylor
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

10.  Phagocytosis of Campylobacter jejuni and its intracellular survival in mononuclear phagocytes.

Authors:  J A Kiehlbauch; R A Albach; L L Baum; K P Chang
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441
View more
  6 in total

1.  Potential Use of Fosfomycin-Tromethamine for Treatment of Recurrent Campylobacter Species Enteritis.

Authors:  Juan Aguilar-Company; Ibai Los-Arcos; Carles Pigrau; Dolors Rodríguez-Pardo; María Nieves Larrosa; Virginia Rodríguez-Garrido; Denisse Sihuay-Diburga; Benito Almirante
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

2.  Complete 6-deoxy-D-altro-heptose biosynthesis pathway from Campylobacter jejuni: more complex than anticipated.

Authors:  Matthew McCallum; Steven D Shaw; Gary S Shaw; Carole Creuzenet
Journal:  J Biol Chem       Date:  2012-07-11       Impact factor: 5.157

Review 3.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

4.  A Cotransformation Method To Identify a Restriction-Modification Enzyme That Reduces Conjugation Efficiency in Campylobacter jejuni.

Authors:  Ximin Zeng; Zuowei Wu; Qijing Zhang; Jun Lin
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

5.  Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model.

Authors:  Beth D Kirkpatrick; Caroline E Lyon; Chad K Porter; Alex C Maue; Patricia Guerry; Kristen K Pierce; Marya P Carmolli; Mark S Riddle; Catherine J Larsson; Douglas Hawk; Elizabeth A Dill; A Fingar; Frederic Poly; Kelly A Fimlaid; Fahmida Hoq; David R Tribble
Journal:  Clin Infect Dis       Date:  2013-07-09       Impact factor: 9.079

6.  Recurrent Campylobacter jejuni Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)-A Case Report.

Authors:  Blair Merrick; Aravind Gokul Tamilarasan; Raphael Luber; Patrick F K Yong; Kuldeep Cheent; Peter M Irving; Manjula Meda; Simon D Goldenberg
Journal:  Infect Dis Rep       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.